

1 Research Article

2 **Optimal Stereotactic Body Radiotherapy Dosage For Hepatocellular Carcinoma**

3

4 **Ting-Shi Su** ^{1,2*}, **Ying Zhou** ², **Yong Huang** ², **Tao Cheng** ², **Ping Liang** ², **Shi-Xiong Liang** ¹,
5 **Le-Qun Li** ^{3,4,*}

6 ¹Department of Radiation Oncology, Guangxi Medical University Cancer Hospital,
7 Nanning, 530001, Guangxi Zhuang Autonomous Region, China;

8 ²Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese
9 Medical University, Nanning 530001, Guangxi Zhuang Autonomous Region, China.

10 ³Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital,
11 Nanning, 530001, Guangxi Zhuang Autonomous Region, China.

12 ⁴Guangxi Liver Cancer Diagnosis and Treatment Engineering and Technology Research
13 Center, Nanning 530021, PR China.

14 Y.Z.: zhyish@163.com; Y.H.: 13978623908@163.com; T.C.: rkct123@163.com; P.L.:
15 13878111698@163.com; L-X. L: shixiang@vip.sina.com

16 *Correspondence: T.-S. S.: sutingshi@163.com; Tel.: +86-18878708186. L.-Q. L.:
17 Li_lequn@263.net; Tel. : +86-13807716079.

18

19 **Abstract:**

20 **Background and purpose:** The optimal dose and fractionation scheme of stereotactic body
21 radiation therapy (SBRT) for hepatocellular carcinoma (HCC) remains unclear due to
22 different tolerated liver volumes and degrees of cirrhosis. We compared the effectiveness of
23 stereotactic body radiation therapy dosing regimens for hepatocellular carcinoma (HCC).

24 **Methods and materials:** This single-center retrospective study included 604 patients treated
25 during 2011-2017. Biologically effective dose (BED₁₀) and equivalent dose in 2 Gy fractions
26 (EQD₂) were assumed at an α/β ratio of 10. Overall survival (OS), local recurrence-free rate
27 (LRF), intrahepatic recurrence-free rate (IRF), and progression-free survival (PFS) was
28 evaluated in univariable and propensity-score matched analyses.

29 **Results:** Median tumor size was 5.2 cm (interquartile range [IQR], 1.1-21.0). Median follow-
30 up was 31 months in surviving patients (IQR, 3-82). High radiotherapy dose correlated with
31 better OS, PFS, LRF and IRF. Different post-SBRT OS, PFS, LRF and IRF rates were observed
32 for stereotactic ablative radiotherapy (SART) with BED₁₀ \geq 100 Gy, SBRT with EQD₂ \geq 74 Gy to
33 BED₁₀ < 100 Gy, and stereotactic conservative radiotherapy (SCRT) with EQD₂ < 74 Gy.

34 **Conclusions:** High radiotherapy dose correlated with better outcomes. If tolerated by normal
35 tissue, we recommend SART as a first-line ablative dose or SBRT as a second-line radical dose.
36 Otherwise, SCRT is recommended as palliative irradiation.

37 Key words: Hepatocellular Carcinoma, Radiotherapy Dosage, Stereotactic Body
38 Radiotherapy, Survival Rate

39

40 1. Introduction

41 Hepatocellular carcinoma (HCC) is highly prevalent in many Asian countries and

42 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

43 cause of cancer-related deaths and the fourth most commonly diagnosed cancer among men
44 [1]. HCC is resectable in only 10–40% of newly diagnosed patients. Liver resection,
45 transplantation, percutaneous ethanol injection, or radiofrequency ablation (RFA) are the
46 standard treatments for early-stage HCC [2].

47 The use of external beam radiation therapy (EBRT), specifically including stereotactic
48 body radiation therapy (SBRT), is increasing in popularity [3-7]. It is commonly recommended
49 as an alternative treatment in medically inoperable patients, as a result of its rapid adoption in
50 clinical practice worldwide [8-10]. SBRT for primary HCC provides high rates of durable local
51 control (89–100%) [4,11-14], but there is no clear evidence of a dose-survival relationship among
52 commonly-utilized radiation therapy schedules. Increasing radiotherapy (RT) dose was
53 associated with improved overall survival in patients treated with SBRT for stage I non-small-
54 cell lung cancer [15-17]. However, the optimal dose and fractionation scheme of SBRT for HCC
55 remains unclear. Therefore, in this retrospective study, we aimed to analyze the dose-survival
56 relationship in patients undergoing SBRT for HCC by using data from a large cohort from
57 Guangxi Zhuang Autonomous Region in China.

58 2. Results

59 2.1. Baseline characteristics

60 From January 1st, 2011 to March 31st, 2017, 678 primary liver cancer patients were treated
61 with SBRT. Twenty-nine cases of intrahepatic cholangiocarcinoma, 25 cases for which complete
62 data was lacking, and 19 cases that were lost to follow-up were excluded; finally, a total of 604
63 patients were enrolled in this study (Figure S1). Based on our previous studies [18,19], the RT
64 dose was classified into three levels: stereotactic ablative radiotherapy (SART, also known as
65 SABR) was defined as a first-line ablative dose of BED10 ≥ 100 Gy, SBRT was defined as a
66 second-line radical dose of EQD2 >74 Gy to BED10 <100 Gy, and stereotactic conservative
67 radiotherapy (SCRT) was defined as palliative irradiation of EQD2 <74 Gy. The demographic
68 and clinical characteristics of the patients and their treatment are summarized in Table 1.
69

70 **Table 1. Patient and Treatment Characteristics for Different Dose Groups**

Factor	Level	SART	SBRT	SCRT	p-value	Test
Total number		259	164	181		
Gender	male	221 (85.3%)	141 (86.0%)	157 (86.7%)	0.92	Pearson's chi-square
Age, mean (SD)		54.9 (12.5)	54.7 (13.1)	52.5 (12.1)	0.11	ANOVA
Recurrence/residual disease		122 (47.1%)	81 (49.4%)	108 (59.7%)	0.028	Pearson's chi-square
HBeAg status	Positive	188 (72.6%)	116 (70.7%)	123 (68.0%)	0.20	Pearson's chi-square
	Negative	33 (12.7%)	25 (15.2%)	38 (21.0%)		
	Unknown	38 (14.7%)	23 (14.0%)	20 (11.0%)		

PT, mean (SD)		13.67 (1.76)	13.66 (1.60)	13.58 (2.03)	0.86	ANOV A
Total bilirubin, mean (SD)		20.38 (47.93)	21.83 (36.41)	18.23 (15.90)	0.67	ANOV A
Albumin, mean (SD)		37.82 (5.524)	36.75 (5.44)	35.72 (5.18)	<0.001	ANOV A
Direct bilirubin, mean (SD)		10.91 (31.83)	11.06 (22.54)	9.78 (11.55)	0.86	ANOV A
AST, mean (SD)		42.60 (36.67)	47.05 (36.87)	51.55 (41.76)	0.054	ANOV A
ALT, mean (SD)		41.07 (47.27)	42.14 (42.10)	43.67 (41.63)	0.83	ANOV A
Child-Pugh class	A	210 (82.4%)	132 (80.5%)	137 (78.3%)	0.82	Pearso n's chi- square d
	B	43 (16.9%)	30 (18.3%)	35 (20.0%)		
	C	2 (0.8%)	2 (1.2%)	3 (1.7%)		
ALBI grade	1	113 (43.6%)	59 (36.0%)	48 (26.5%)	0.003	Pearso n's chi- square d
	2	137 (52.9%)	93 (56.7%)	123 (68.0%)		
	3	9 (3.5%)	12 (7.3%)	10 (5.5%)		
BCLC stage	A	153 (59.3%)	52 (31.7%)	35 (19.4%)	<0.001	Pearso n's chi- square d
	B	43 (16.7%)	37 (22.6%)	35 (19.4%)		
	C	59 (22.9%)	73 (44.5%)	107 (59.4%)		
	D	3 (1.2%)	2 (1.2%)	3 (1.7%)		
size, mean (SD)		4.415 (2.74)	7.13 (7.09)	8.61 (5.58)	<0.001	ANOV A
Hg, mean (SD)		125.96 (20.35)	125.50(21. 44)	121.15(20. 72)	0.089	ANOV A
PLT, mean (SD)		162.19 (85.01)	171.48 (91.39)	179.21 (93.15)	0.24	ANOV A
RBC, mean (SD)		4.30 (.703)	4.35 (.82)	4.23 (.76)	0.43	ANOV A
WBC, mean (SD)		6.06 (2.67)	5.82 (2.18)	6.99 (3.81)	0.003	ANOV A


71 *Abbreviations: AFP, alpha fetal protein; ALBI, albumin-bilirubin score; ALT, alanine*
72 *aminotransferase; ANOVA, analysis of variance; AST, aspartate aminotransferase; BCLC, Barcelona*
73 *Clinic Liver Cancer; HBsAg, hepatitis B surface antigen; Hg, haemoglobin; PLT, platelet; INR,*
74 *International Normalised Ratio; PT, prothrombin time; RBC, red blood cells; SART, stereotactic ablative*
75 *radiotherapy; SBRT, stereotactic body radiation therapy; SCRT, stereotactic conservative radiotherapy;*
76 *SD, standard deviation; WBC, white blood cells.*

77 **2.2. Increasing radiation therapy dose as a prognostic factor for overall survival (OS), local**
78 **recurrence-free rate (LRF), intrahepatic recurrence-free rate (IRF), and progression-free**
79 **survival (PFS)**

80 Among the included patients, the median tumor size was 5.2 cm (interquartile range [IQR],
81 1.1–21.0 cm). The median follow-up was 31 months in surviving patients (IQR, 3–82 months).

82 When RT dose was used to classify the patients into the SART, SBRT, and SCRT groups, 3
 83 notably different curves were observed for long-term post-SBRT survival. The 1-, 3-, and 5-year
 84 OS rates were 82.2%, 59.4%, and 55.3% in the SART group; 62.6%, 34.6%, and 26.4% in the SBRT
 85 group; and 49.9%, 24.5%, and 13.8% in the SCRT group, respectively (log-rank $P < 0.0001$; Figure
 86 1A). The 1-, 3-, and 5-year PFS rates were 58.0%, 35.1%, and 26.5% in the SART group; 40.2%,
 87 14.3%, and 9.2% in the SBRT group; and 21.4%, 7.1%, and 5.3% in the SCRT group, respectively
 88 (log-rank $P < 0.0001$; Figure 1B). The 1-, 3-, and 5-year LRF rates were 83.4%, 67.3%, and 63.1%
 89 in the SART group; 79.5%, 57.6%, and 57.6% in the SBRT group; and 69.5%, 54.4%, and 43.5%
 90 in the SCRT group, respectively (log-rank $P = 0.0141$; Figure 1C). The 1-, 3-, and 5-year IRF rates
 91 were 82.2%, 59.4%, and 55.3% in the SART group; 62.6%, 34.6%, and 26.4% in the SBRT group;
 92 and 49.9%, 24.5%, and 13.8% in the SCRT group, respectively (log-rank $P < 0.0001$; Figure 1).

93



94

95 **Figure 1.** Before propensity score matching, SART versus SBRT or SCRT: a) overall survival, b)
 96 progression-free survival, c) local recurrence-free rate, d) intrahepatic recurrence-free rate

97 Several variables differed substantively between the 3 groups, including the
 98 recurrence/residual disease status, level of albumin, ALBI grade, tumor size, and BCLC stage.
 99 After propensity score matching, there was no significant difference among the groups and the
 100 balance of variables was observed to be markedly improved in the matched cohorts (Tables 2
 101 and 3).

102

103 **Table 2** Distribution of variables in the matched cohorts SART and SBRT after propensity score
 104 matching

Factor	Level	SART	SBRT	p-value	Test
N		143	143		
Gender	Male	119 (83.2%)	123 (86.0%)	0.51	Pearson's chi-squared
Age, mean (SD)		53.2 (13.0)	54.4 (13.0)	0.44	Two sample t test

PT, mean (SD)		14.0 (1.9)	13.6 (1.6)	0.12	Two sample t test
Total bilirubin, mean (SD)		23.5 (63.4)	21.0 (37.2)	0.68	Two sample t test
Albumin, mean (SD)		37.4 (5.5)	37.0 (5.4)	0.57	Two sample t test
AST, mean (SD)		45.9 (37.7)	42.8 (29.8)	0.44	Two sample t test
ALT, mean (SD)		46.4 (58.7)	41.6 (42.2)	0.43	Two sample t test
WBC, mean (SD)		6.59 (3.02)	5.66 (2.15)	0.022	Two sample t test
RBC, mean (SD)		4.22 (.68)	4.38 (.80)	0.18	Two sample t test
PLT, mean (SD)		177.6 (90.8)	165.9 (88.9)	0.41	Two sample t test
Tumour size, mean (SD)		5.30 (3.21)	5.97 (3.10)	0.11	Two sample t test
Recurrence/residual disease	Yes	81 (56.6%)	72 (50.3%)	0.29	Pearson's chi-squared
HBsAg status	Positive	94 (65.7%)	105 (73.4%)	0.16	Pearson's chi-squared
	Negative	19 (13.3%)	20 (14.0%)		
	Unknown	30 (21.0%)	18 (12.6%)		
ALBI score, mean (SD)		-2.397 (.559)	-2.371 (.526)	0.69	Two sample t test
ALBI grade	1	57 (39.9%)	55 (38.5%)	0.73	Pearson's chi-squared
	2	80 (55.9%)	79 (55.2%)		
	3	6 (4.2%)	9 (6.3%)		
Total dose, mean (SD)		43.6 (3.7)	42.8 (3.1)	0.041	Two sample t test
Fraction	1	6 (4.2%)	0 (0.0%)	<0.001	Pearson's chi-squared
	2	2 (1.4%)	1 (0.7%)		

	3	124 (86.7%)	54 (37.8%)		
	4	8 (5.6%)	80 (55.9%)		
	5	3 (2.1%)	7 (4.9%)		
	6	0 (0.0%)	1 (0.7%)		
Child-Pugh score	5	85 (59.4%)	77 (53.8%)	0.75	Pearson's chi-squared
	6	33 (23.1%)	41 (28.7%)		
	7	13 (9.1%)	16 (11.2%)		
	8	8 (5.6%)	5 (3.5%)		
	9	3 (2.1%)	2 (1.4%)		
	10	1 (0.7%)	1 (0.7%)		
	13	0 (0.0%)	1 (0.7%)		
AFP status	<8	41 (29.5%)	34 (23.8%)	0.18	Pearson's chi-squared
	8-200	51 (36.7%)	38 (26.6%)		
	>200	40 (28.8%)	62 (43.4%)		
	Unknown	7 (5.0%)	9 (6.3%)		
BCLC stage	A	58 (40.6%)	52 (36.4%)	0.80	Pearson's chi-squared
	B	35 (24.5%)	33 (23.1%)		
	C	48 (33.6%)	56 (39.2%)		
	D	2 (1.4%)	2 (1.4%)		

105
106
107

Table 3 Distribution of variables in the matched cohorts SBRT and SCRT after propensity score matching

Factor	Level	SBRT	SCRT	p-value	Test
N		160	160		
Gender		138 (86.3%)	137 (85.6%)	0.87	Pearson's chi-squared
Age, mean (SD)		54.5 (13.2)	52.9 (12.1)	0.25	Two sample t test
PT, mean (SD)		13.6 (1.6)	13.5 (2.0)	0.58	Two sample t test
Total bilirubin, mean (SD)		21.9 (36.8)	17.6 (15.3)	0.18	Two sample t test
Albumin, mean (SD)		36.7 (5.4)	35.8 (5.1)	0.14	Two sample t test
AST, mean (SD)		47.3 (37.2)	52.8 (43.5)	0.23	Two sample t test

ALT, mean (SD)		42.4 (42.5)	43.9 (43.0)	0.76	Two sample t test
WBC, mean (SD)		5.827 (2.18)	7.10 (3.93)	0.002	Two sample t test
RBC, mean (SD)		4.34 (.83)	4.26 (.75)	0.45	Two sample t test
PLT, mean (SD)		172.4 (92.4)	183.6 (93.3)	0.34	Two sample t test
Tumour size, mean (SD)		7.53 (7.15)	8.18 (5.75)	0.16	Two sample t test
Recurrence/residual disease	Yes	79 (49.4%)	95 (59.4%)	0.13	Pearson's chi-squared
HBsAg status	Positive	113 (70.6%)	108 (67.5%)	0.22	Pearson's chi-squared
	Negative	24 (15.0%)	35 (21.9%)		
	Unknown	23 (14.4%)	17 (10.6%)		
ALBI score, mean (SD)		-2.338 (.534)	-2.281 (.507)	0.33	Two sample t test
ALBI grade	1	57 (35.6%)	43 (26.9%)	0.11	Pearson's chi-squared
	2	91 (56.9%)	110 (68.8%)		
	3	12 (7.5%)	7 (4.4%)		
Total dose, mean (SD)		42.5 (3.1)	40.1 (4.6)	<0.001	Two sample t test
Fraction	2	1 (0.6%)	0 (0.0%)	<0.001	Pearson's chi-squared
	3	68 (42.5%)	39 (24.4%)		
	4	83 (51.9%)	75 (46.9%)		
	5	7 (4.4%)	42 (26.3%)		
	6	1 (0.6%)	4 (2.5%)		
Child-Pugh score	5	83 (51.9%)	75 (46.9%)	0.52	Pearson's chi-squared
	6	46 (28.7%)	52 (32.5%)		
	7	18 (11.3%)	21 (13.1%)		
	8	7 (4.4%)	7 (4.4%)		
	9	4 (2.5%)	1 (0.6%)		
	10	1 (0.6%)	2 (1.3%)		
	11	0 (0.0%)	2 (1.3%)		

	13	1 (0.6%)	0 (0.0%)		
AFP status	<8	37 (23.1%)	35 (21.9%)	0.90	Pearson's chi-squared
	8-200	39 (24.4%)	37 (23.1%)		
	>200	75 (46.9%)	81 (50.6%)		
	Unknown	9 (5.6%)	7 (4.4%)		
BCLC stage	A	48 (30.0%)	34 (21.3%)	0.20	Pearson's chi-squared
	B	37 (23.1%)	33 (20.6%)		
	C	73 (45.6%)	90 (56.3%)		
	D	2 (1.3%)	3 (1.9%)		

108

109

110

111

112

113

114


115

116

117

118

For the comparison of SART and SBRT, the matching procedure resulted in the selection of 143 patient pairs. The 1-, 3-, and 5-year OS rates were 76.3%, 50.6%, and 48.0% in the SART group and 65.8%, 36.3%, and 33.0% in the SBRT group, respectively (log-rank $P=0.0167$; Figure 2A). The 1-, 3-, and 5-year PFS rates were 51.7%, 31.4%, and 25.6% in the SART group and 43.2%, 15.3%, and 9.9% in the SBRT group, respectively (log-rank $P=0.0058$; Figure 2B). The 1-, 3-, and 5-year LRF rates were 85.8%, 69.5%, and 64.0% in the SART group and 80.5%, 63.8%, and 57.6% in the SBRT group, respectively (log-rank $P=0.2008$; Figure 2C). The 1-, 3-, and 5-year IRF rates were 68.4%, 51.4%, and 43.8% in the SART group and 59.0%, 30.4%, and 26.6% in the SBRT group, respectively (log-rank $P=0.0051$; Figure 2D)



119

120

121

122

123

124


125

126

Figure 2. After propensity score matching, SART versus SBRT: a) overall survival, b) progression-free survival, c) local recurrence-free rate, d) intrahepatic recurrence-free rate.

For the comparison of SBRT and SCRT, the matching procedure resulted in the selection of 160 patient pairs. The 1-, 3-, and 5-year OS rates were 71.6%, 33.7%, and 25.7% in the SBRT

127 group and 49.9%, 24.8%, and 13.9% in the SCRT group, respectively (log-rank $P=0.0158$; Figure
 128 3A). The 1-, 3-, and 5-year PFS rates were 41.3%, 13.7%, and 8.8% in the SBRT group and 22.3%,
 129 7.0%, and 5.3% in the SCRT group, respectively (log-rank $P=0.0004$; Figure 3B). The 1-, 3-, and
 130 5-year LRF rates were 80.9%, 57.2%, and 57.2% in the SBRT group and 70.7%, 55.9%, and 44.7%
 131 in the SCRT group, respectively (log-rank $P=0.116$; Figure 3C). The 1-, 3-, and 5-year IRF rates
 132 were 58.8%, 31.3%, and 23.8% in the SBRT group and 44.9%, 26.3%, and 21.0% in the SCRT
 133 group, respectively (log-rank $P=0.041$; Figure 3D).
 134




135
136

137
138
139

Figure 3. After propensity score matching, SBRT versus SCRT: a) overall survival, b) progression-free survival, c) local recurrence-free rate, d) intrahepatic recurrence-free rate.

140 2.3. Subgroup analysis of radiation therapy total dose for OS

141 Additionally, we found a significant association between higher total dose (TD) and better
 142 OS. The 1-, 3-, and 5-year OS rates were 71.4%, 49.7%, and 43.6% in the TD ≥ 42 Gy group and
 143 56.5%, 23.5%, and 20.5% in the TD < 42 Gy group, respectively (log-rank $P < 0.0001$; Figure 4A).
 144 Further, we found that the use of fewer fractions was association with significantly better OS.
 145 The 1-, 3-, and 5-year OS rates were 74.6%, 47.8%, and 45.3% in the ≤ 3 fractions group and 56.7%,
 146 35.1%, and 20.3% in the ≥ 4 fractions group, respectively (log-rank $P=0.0002$; Figure 4B).
 147



148
149
150
151

Figure 4. Different post-SBRT overall survival: a), Total doses ≥ 42 Gy versus < 42 Gy group; b) fractions ≤ 3 versus ≥ 4 fractions group.

152

2.4. Multivariable analysis of radiation therapy dose for OS

153
154
155
156
157

In a multivariable analysis, high RT dose was associated with significantly improved OS ($P < 0.05$). The other clinical factors that had significant associations with OS were age ≥ 60 years, ALBI scores, alanine aminotransferase (ALT), and BCLC stage (all $P < 0.05$, Table 4).

Table 4. Multivariable predictors of overall survival

Factor	level	HR	SE	P	[95% Conf. Interval]	
Gender	male	1.000				
	female	0.843	0.173	0.405	0.565	1.259
Age	<60	1.000				
	≥ 60	1.424	0.241	0.036	1.023	1.984
BCLC stage	A	1.000				
	B	2.196	0.518	0.001	1.384	3.486
	C	3.555	0.724	0.000	2.385	5.300
	D	1.929	1.259	0.314	0.537	6.929
HCC status	recurrence/residual	1.000				
	primary	0.850	0.131	0.290	0.629	1.149
AFP status	<8	1.000				
	8-200	0.662	0.406	0.501	0.199	2.201
	>200	0.944	0.574	0.924	0.286	3.109
	Unknown	1.213	0.728	0.747	0.374	3.933
RT dosage	SART	1.000				
	SBRT	1.506	0.312	0.048	1.003	2.260
	SCRT	1.846	0.397	0.004	1.212	2.813
ALBI scores		1.760	0.340	0.003	1.206	2.569
Size		1.004	0.025	0.861	0.957	1.054
AST		1.003	0.002	0.177	0.999	1.006
ALT		0.995	0.002	0.022	0.990	0.999
WBC		1.041	0.025	0.088	0.994	1.091
RBC		1.049	0.138	0.714	0.810	1.359
PLT		1.000	0.001	0.883	0.998	1.002
Hg		0.992	0.005	0.126	0.982	1.002

158 Discussion

159 Precise radiotherapy dose is important but uncertain, especially in HCC that can be treated
160 with radical radiotherapy, because primary HCCs tend to be associated with different tolerated
161 liver volumes and degrees of cirrhosis. In the current study, we classified RT doses into three
162 levels (SART, SBRT, and SCRT) and found that higher RT doses were associated with better OS
163 in both univariable and multivariable analyses. After propensity score matching, BED10 \geq 100
164 Gy and EQD2 \geq 74 Gy continued to be associated with significantly better OS and PFS, which
165 suggests that they conferred significant survival benefits. This finding is consistent with a
166 previous study of SBRT for HCCs that were $>$ 5 cm and lacked tumor thrombus, lymph node
167 involvement, and extrahepatic metastasis. In that study, BED10 \geq 100 Gy and EQD2 \geq 74 Gy
168 were significant prognostic factors for OS, progression-free survival, local relapse-free survival,
169 and distant metastasis-free survival [18]. Scorsetti et al. [20] studied 43 patients with HCC (1–3
170 lesions, \leq 6 cm) who received SBRT and found that higher BED10 was significantly correlated
171 with improved local control and OS. The 1-year local control rate was 100% in patients treated
172 with BED10 \geq 100 Gy, while it was 52.0% in patients treated with BED10 $<$ 100 Gy, with median
173 OS times of 27.0 versus 8.1 months ($P<$ 0.05). We have speculated that individualized doses of
174 SBRT might be effective for HCC because primary HCCs tend to be associated with different
175 degrees of cirrhosis and liver volumes. In our study, RT doses were classified into three levels:
176 SART, SBRT and SCRT. If tolerated by normal tissue, a first-line ablative dose of SART with a
177 BED10 \geq 100 Gy or a second-line radical dose of SBRT with an EQD2 \geq 74 Gy is recommended.
178 Otherwise, palliative irradiation via SCRT with EQD2 $<$ 74 Gy is recommended.

179 Wahl et al. [4] reported that SBRT appears to be a reasonable first-line treatment for
180 inoperable large HCC. They found no significant difference in OS between the SBRT and RFA
181 groups. One-year OS was 74% after SBRT and 70% after RFA, while 2-year OS was 46% after
182 SBRT and 53% after RFA. Wahl et al. also observed that, for tumors sized \geq 2 cm, SBRT was
183 superior to RFA in terms of freedom from local progression. On the other hand, Rajyaguru et
184 al. [21] reported unfavorable OS in patients receiving SBRT, with 5-year OS rates of 19.3% in
185 the SBRT group and 29.8% in the RFA group. Their study included a relatively small sample
186 population of patients receiving treatment with SBRT ($n=275$), and the data for their study was
187 retrieved from a US national cancer database. RT dose was unknown for 40 (14%) of the 275
188 patients receiving SBRT. Of the 235 with known doses, 60 (26%) received lower radiation doses
189 ($<$ 40 Gy). A follow-up analysis of patients receiving ablative doses showed no OS difference in
190 comparison with patients receiving RFA [22]. In the current study, which had a larger sample
191 population ($n=604$), the 1-, 3-, and 5-year OS rates were 82.2%, 59.4%, and 55.3% in the SART
192 group; 62.6%, 34.6%, and 26.4% in the SBRT group; and 49.9%, 24.5%, and 13.8% in the SCRT
193 group, respectively ($P<$ 0.0001). In a previous study of the same patient cohort, there was no
194 difference in long-term survival outcomes between SABR and liver resection for small HCCs
195 (\leq 5 cm) with CP-A cirrhosis. The 5-year OS rates were 70.0% and 64.4% in the in the SABR and
196 liver resection groups, respectively [5]. Therefore, precise radiotherapy dose is important,
197 especially in HCC that can be treated with radical radiotherapy.

198 In the current study, a \geq 42-Gy total dose and \leq 3 fractions were also important indices that
199 were associated with clinical curative effect. This result may be beneficial to the clinical
200 application of SBRT in the treatment of HCC, considering that this has been rapidly adopted
201 as a preferred treatment choice worldwide. Jang et al. [23] reported SBRT doses escalated from
202 33 Gy in 3 fractions to 60 Gy in 3 fractions for HCC (longest diameter \leq 7 cm). The 2-year OS
203 rates for patients treated with doses $>$ 54 Gy, 45–54 Gy, and $<$ 45 Gy were 71%, 64%, and 30%,
204 respectively, while the 2-year local control rates were 100%, 78%, and 64%, respectively. Six
205 patients showed a deterioration in the CP score to \geq 2 within 3 months, and 5 patients
206 experienced grade \geq 3 gastrointestinal toxicity. In our clinical practice in China, a fractionated
207 scheme of 45 Gy in 3 fractions (BED10=112.5 Gy and EQD2=93.8 Gy) was applied in a multi-
208 institutional, single-arm Phase II trial of SBRT for the treatment of HCC in patients with

209 unifocal liver tumors within ≤ 5 cm in diameter, or 2–3 lesions with a maximum lesion size of 3
210 cm for each lesion (NCT 02363218). Thirteen patients presented with grade ≥ 2 hepatic adverse
211 reaction and 8 patients presented with decreases in CP classification. Total liver volume $>1,162$
212 mL and normal liver volume $>1,148$ mL should be ensured to improve therapeutic safety [24].
213 Additionally, another fractionated scheme of 39–50 Gy in 3–5 fractions were applied in our
214 single-institutional Phase II trial of SBRT for the treatment of HCC in patients with 1–3 nodular
215 HCC lesions with a total diameter <10 cm (ChiCTR-IIC-16008233). The dose-volume constraints
216 for the liver were the absolute normal liver volume spared from at least 15 Gy (VS15) >700 mL
217 and/or the percentage (%) of normal liver volume receiving more than 15 Gy (V15) $<1/3$ normal
218 liver volume. If tolerated by normal tissue, a first-line ablative dose of SART with a BED10 ≥ 100
219 Gy or a second-line radical dose of SBRT with an EQD2 ≥ 74 Gy was recommended. Otherwise,
220 palliative irradiation via SCRT with EQD2 <74 Gy was recommended. No case of classic
221 radiation-induced liver disease was observed. Regarding the Child-Pugh (CP) scores following
222 SBRT, 20 (23.5%) and 12 (14.2%) patients had CP+ ≥ 1 and ≥ 2 , respectively. We further found
223 that V15, VS10 (the absolute normal liver volume spared from at least 10 Gy), and pre-CP were
224 optimal predictors for radiation-induced hepatic toxicity (RIHT: CP+ ≥ 1 and ≥ 2) modelling. We
225 built normal tissue complication probability models and nomograms for RIHT predication in
226 order to obtain individual constraints for each patient. VS10 ≥ 416.2 mL and V15 $<33.1\%$ for
227 RIHT (≥ 1) risk stratification, and VS10 ≥ 621.8 mL and V15 $<21.5\%$ for RIHT (≥ 2) may provide
228 some references for liver constraint selection (table 5) [19].

229 **Table 5 Recommendations for 3-5 fractions SBRT treatment**

Dosimetric constraints for liver	Radiation dose for GTV
V15 $<21.5\%$, VS10 ≥ 621.8 mL	SART: BED10 ≥ 100 Gy
V15 $<33.1\%$, VS10 ≥ 416.2 - 621.8 mL	SBRT: EQD2 ≥ 74 Gy
Without above conditions or Child-Pugh $\geq B7$ class	SCRT: EQD2 <74 Gy

230
231 BED10 can serve as a simple and straightforward means to perform a comparative and
232 effective analysis among a large variety of dose fractionations prescribed. The clinical efficacy
233 of higher BED10 values has been fully recognized in the use of SBRT for the treatment of lung
234 cancer. Kestin et al. [16] analyzed 505 patients receiving SBRT for the treatment of non-small-
235 cell lung cancer at 5 institutions, and found that local recurrence was significantly decreased
236 for those treated with BED10 <105 Gy as compared to those treated with BED10 >105 Gy (15%
237 vs. 4%). Onishi et al. [17] analyzed 257 patients at 14 institutions treated with SBRT for lung
238 cancer and found a 5-year local control of 37% versus 84% for patients treated with an isocenter
239 of BED10 <100 Gy versus BED10 >100 Gy. Koshy et al. [15] analyzed 498 patients receiving
240 SBRT for early stage non-small-cell lung cancer, and found a survival benefit with BED10 >150
241 Gy in T2 tumor patients.

242 The present study has some limitations. First, the calculation of BED10 using an α/β ratio
243 of 10 from the linear-quadratic model is controversial, even though it is commonly used.
244 Second, our study had a single-center retrospective design, and used data from a larger cohort
245 of patients from Guangxi Zhuang Autonomous Region in China. Third, we observed strong
246 associations between RT dose/fractionation and other prognostic factors, including BCLC class,
247 tumor size, and ALBI grade. We have speculated that individualized doses of SBRT might be

248 effective for HCC because primary HCCs tend to be associated with different degrees of
249 cirrhosis and liver volumes. In general, patients with small tumors, BCLC stage A, and/or low
250 ALBI score received higher RT doses, whereas those with larger tumors, BCLC B, C, D, and/or
251 higher ALBI score received lower RT doses. This selection bias may not have been completely
252 addressed with the multivariable analysis. For this reason, we also applied propensity score
253 matching as an additional means of reducing selection bias and confounding. Applying
254 propensity score matching created a quasi-randomized experiment. After matching, there was
255 no significant difference in pre-RT covariates among the treatment groups and the balance of
256 variables in the matched cohorts was markedly improved, but the associations between higher
257 doses and better OS and PFS remained, suggesting that they are not the product of biases.
258 Fourth, Short-term liver toxicity has been reported, but classic radiation-induced liver disease
259 was not observed during the follow-up period. SBRT dosing regimens for HCC are generally
260 tolerable, and further research is being conducted on long-term OS and liver toxicity. ChiCTR-
261 IIC-16008233 (39–50 Gy in 3–5 fractions based on SART, SBRT, SCRT) and NCT 02363218 (45Gy
262 in 3 fractions) are ongoing clinical trials in our hospital in China. Fifth, this study was
263 performed in an area in which hepatitis B is endemic; therefore, it is unclear whether the
264 dosimetric findings are applicable to HCC cases associated with other risk factors.

265 4. Materials and Methods

266 4.1. Patients

267 A dataset collected from Guangxi Zhuang Autonomous Region in China was used in this
268 retrospective study. Radiation therapy for liver cancer has been used in our region for more
269 than 20 years [5,25]. HCC diagnosis was established based on histopathology or according to
270 the clinical criteria for diagnosis of HCC [9]. The eligibility criteria were as follows: patients
271 with primary HCC treated with SBRT from January 1, 2011 to March 31, 2017. The exclusion
272 criteria were as follows: (a) prior history of abdominal conventional radiotherapy, (b)
273 intrahepatic cholangiocellular carcinoma, (c) gallbladder metastases, and/or (d) liver
274 metastases. This study complied with the tenets of the Declaration of Helsinki. All study
275 participants provided informed consent, and the study design was approved by the
276 appropriate ethics review board.

277 4.2. Stereotactic body radiation therapy

278 The SBRT technique used at our institution has been previously described [5,12,18,19].
279 Briefly, the patients were immobilized with a customized external vacuum-type. SBRT was
280 delivered using the CyberKnife system (Accuray Incorporated, Sunnyvale, CA, USA), with 6
281 Mv photons. Three or four gold markers were inserted into the surrounding area of the tumor
282 or into tumor tissue. Gross tumor volume (GTV) was delineated as the visible tumor, based on
283 results of computed tomography and/or magnetic resonance imaging. Planning target volume
284 (PTV) was established as a 0–5 mm expansion of the GTV. No internal target volume (ITV) was
285 created because tracking was used. A dose of 28–55 Gy was administered in 1–6 fractions on
286 consecutive days at the 50–85% isodose line that covered at least 97% of the PTV. Total doses
287 and fractionation schedules were chosen according to size and dose-volume constraints of the
288 organs at risk.

289 4.3. Calculated values

290 Biologically effective dose (BED10) and equivalent dose in 2 Gy fractions (EQD2) were
291 assumed at an α/β ratio of 10, for rapidly proliferating tumor cells. EQD was calculated as: $d \times n$
292 $\{(\alpha/\beta+d)/(\alpha/\beta+dx)\}$; BED was calculated as: $d \times n \{1+d/(\alpha/\beta)\}$; (d=dose, n=fraction and dx=2).

293 OS rates were calculated from the date of initiation of SBRT until the date of final follow-up or
294 death.

295 4.4. Statistical analysis

296 OS, PFS LRF, and LFR rates were estimated using the Kaplan–Meier method and compared
297 between groups using the log-rank test. OS was calculated starting from the date of the first
298 treatment until the date of the final follow-up or death. LFR was calculated starting from the
299 date of the first treatment until the date of local recurrence or progression. IFR was calculated
300 starting from the date of the first treatment until the date of intrahepatic recurrence or
301 progression. PFS was calculated starting from the date of the first treatment until the date of
302 recurrence or progression or death. Additionally, multivariate regression analyses of survival
303 were performed using the Cox proportional hazards model. The multivariate regression
304 included all characteristics that were significant in univariate analyses, as well as clinical
305 characteristics that could be associated with survival based on previously published evidence.
306 Student’s t and Mann-Whitney U tests were used to analyze continuous variables. For
307 categorical variables, the χ^2 and Fisher’s exact tests were used. In our analyses of the effects of
308 treatments, propensity score matching methods were applied to reduce the potential for
309 selection bias and confounding. Matching was performed on a 1:1 basis and the caliper value
310 for matching was set to 0.1. Age, sex, tumor size, albumin-bilirubin (ALBI) score, and Barcelona
311 Clinic Liver Cancer (BCLC) stage were selected on the basis of this score, and the values were
312 compared with those observed at the baseline. Statistical analyses were performed using Stata
313 15.1 (StataCorp LLC, USA) and SPSS 23.0 (IBM, Armonk, NY). A P-value less than 0.05 was
314 considered statistically significant.

315 5. Conclusions

316 In this large retrospective study, higher RT doses were associated with better survival in
317 patients undergoing SBRT for the treatment of HCC. Individualized doses of SBRT are
318 recommended because patients with HCC have different degrees of cirrhosis and liver volumes.
319 If tolerated by normal tissue, we recommend SART with BED10 ≥ 100 Gy as the first-line
320 ablative dose or SBRT with EQD2 ≥ 74 Gy and BED10 < 100 Gy as the second-line radical dose.
321 Otherwise, SCRT with EQD2 < 74 Gy is recommended as palliative irradiation. Further research
322 is warranted to validate the effects of this novel treatment regimen, and would preferably
323 include multi-institutional prospective studies.

324 **Author Contributions:** Su TS made substantial contributions to conception and design of the
325 study. Su TS, Liang P, Zhou Y, Cheng T and Huang Y made substantial contributions to data
326 acquisition. Su TS made substantial contributions to the analysis and interpretation of the data.
327 All authors participated in drafting the article or revising it critically for important intellectual
328 content. All authors provided final approval of the version to be published.

329 **Funding:** This work was supported by the National Natural Science Foundation of China
330 [81903257], the National Science and Technology Major Special Project [2012ZX10002010001009]
331 and the Scientific Research and Technology Development Program of Guangxi (CN),
332 GuiKeGong [14124003-4], and Guangxi BaGui Scholars’ Special Fund.

333 **Acknowledgements:** We thank all patients who participated in this study and our colleagues
334 in Rui Kang Hospital, such as Zuping Lian, Qiuhua Liu and Encun Hou and so on.

335 **Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the
336 design of the study; in the collection, analyses, or interpretation of data; in the writing of the
337 manuscript, or in the decision to publish the results

338
339

340 **References**

- 341 1. Chen, W.; Zheng, R.; Baade, P.D.; Zhang, S.; Zeng, H.; Bray, F.; Jemal, A.; Yu, X.Q.; He, J.
342 Cancer statistics in china, 2015. *CA Cancer J Clin* **2016**, *66*, 115-132.
- 343 2. European Association For The Study Of The, L.; European Organisation For, R.; Treatment Of,
344 C. East-eortic clinical practice guidelines: Management of hepatocellular carcinoma. *J Hepatol*
345 **2012**, *56*, 908-943.
- 346 3. Murray, L.J.; Dawson, L.A. Advances in stereotactic body radiation therapy for hepatocellular
347 carcinoma. *Semin Radiat Oncol* **2017**, *27*, 247-255.
- 348 4. Wahl, D.R.; Stenmark, M.H.; Tao, Y.; Pollom, E.L.; Caoili, E.M.; Lawrence, T.S.; Schipper,
349 M.J.; Feng, M. Outcomes after stereotactic body radiotherapy or radiofrequency ablation for
350 hepatocellular carcinoma. *J Clin Oncol* **2016**, *34*, 452-459.
- 351 5. Su, T.S.; Liang, P.; Liang, J.; Lu, H.Z.; Jiang, H.Y.; Cheng, T.; Huang, Y.; Tang, Y.; Deng, X.
352 Long-term survival analysis of stereotactic ablative radiotherapy versus liver resection for small
353 hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* **2017**, *98*, 639-646.
- 354 6. Kwon, J.H.; Bae, S.H.; Kim, J.Y.; Choi, B.O.; Jang, H.S.; Jang, J.W.; Choi, J.Y.; Yoon, S.K.;
355 Chung, K.W. Long-term effect of stereotactic body radiation therapy for primary hepatocellular
356 carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy
357 for liver cancer. *BMC cancer* **2010**, *10*, 475.
- 358 7. Sapir, E.; Tao, Y.; Schipper, M.J.; Bazzi, L.; Novelli, P.M.; Devlin, P.; Owen, D.; Cuneo, K.C.;
359 Lawrence, T.S.; Parikh, N.D., *et al.* Stereotactic body radiation therapy as an alternative to
360 transarterial chemoembolization for hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys*
361 **2018**, *100*, 122-130.
- 362 8. Vogel, A.; Cervantes, A.; Chau, I.; Daniele, B.; Llovet, J.; Meyer, T.; Nault, J.C.; Neumann, U.;
363 Ricke, J.; Sangro, B., *et al.* Hepatocellular carcinoma: Esmo clinical practice guidelines for
364 diagnosis, treatment and follow-up. *Ann Oncol* **2018**, *29*, iv238-iv255.
- 365 9. Zhou, J.; Sun, H.C.; Wang, Z.; Cong, W.M.; Wang, J.H.; Zeng, M.S.; Yang, J.M.; Bie, P.; Liu,
366 L.X.; Wen, T.F., *et al.* Guidelines for diagnosis and treatment of primary liver cancer in china
367 (2017 edition). *Liver Cancer* **2018**, *7*, 235-260.
- 368 10. Benson, A.B., 3rd; D'Angelica, M.I.; Abbott, D.E.; Abrams, T.A.; Alberts, S.R.; Saenz, D.A.;
369 Are, C.; Brown, D.B.; Chang, D.T.; Covey, A.M., *et al.* Nccn guidelines insights: Hepatobiliary
370 cancers, version 1.2017. *J Natl Compr Canc Netw* **2017**, *15*, 563-573.
- 371 11. Bibault, J.E.; Dewas, S.; Vautravers-Dewas, C.; Hollebecque, A.; Jarraya, H.; Lacornerie, T.;
372 Lartigau, E.; Mirabel, X. Stereotactic body radiation therapy for hepatocellular carcinoma:
373 Prognostic factors of local control, overall survival, and toxicity. *PLoS One* **2013**, *8*, e77472.
- 374 12. Su, T.S.; Liang, P.; Lu, H.Z.; Liang, J.; Gao, Y.C.; Zhou, Y.; Huang, Y.; Tang, M.Y.; Liang,
375 J.N. Stereotactic body radiation therapy for small primary or recurrent hepatocellular carcinoma
376 in 132 chinese patients. *J Surg Oncol* **2016**, *113*, 181-187.
- 377 13. Sanuki, N.; Takeda, A.; Oku, Y.; Mizuno, T.; Aoki, Y.; Eriguchi, T.; Iwabuchi, S.; Kunieda, E.
378 Stereotactic body radiotherapy for small hepatocellular carcinoma: A retrospective outcome
379 analysis in 185 patients. *Acta Oncol* **2014**, *53*, 399-404.
- 380 14. Huertas, A.; Baumann, A.S.; Saunier-Kubs, F.; Salleron, J.; Oldrini, G.; Croise-Laurent, V.;
381 Barraud, H.; Ayav, A.; Bronowicki, J.P.; Peiffert, D. Stereotactic body radiation therapy as an

- 382 ablative treatment for inoperable hepatocellular carcinoma. *Radiother Oncol* **2015**, *115*, 211-
383 216.
- 384 15. Koshy, M.; Malik, R.; Weichselbaum, R.R.; Sher, D.J. Increasing radiation therapy dose is
385 associated with improved survival in patients undergoing stereotactic body radiation therapy for
386 stage i non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys* **2015**, *91*, 344-350.
- 387 16. Kestin, L.; Grills, I.; Guckenberger, M.; Belderbos, J.; Hope, A.J.; Werner-Wasik, M.; Sonke,
388 J.J.; Bissonnette, J.P.; Xiao, Y.; Yan, D., *et al.* Dose-response relationship with clinical outcome
389 for lung stereotactic body radiotherapy (sbrt) delivered via online image guidance. *Radiother*
390 *Oncol* **2014**, *110*, 499-504.
- 391 17. Onishi, H.; Shirato, H.; Nagata, Y.; Hiraoka, M.; Fujino, M.; Gomi, K.; Niibe, Y.; Karasawa,
392 K.; Hayakawa, K.; Takai, Y., *et al.* Hypofractionated stereotactic radiotherapy (hypofxsrt) for
393 stage i non-small cell lung cancer: Updated results of 257 patients in a japanese multi-
394 institutional study. *J Thorac Oncol* **2007**, *2*, S94-100.
- 395 18. Su, T.S.; Lu, H.Z.; Cheng, T.; Zhou, Y.; Huang, Y.; Gao, Y.C.; Tang, M.Y.; Jiang, H.Y.; Lian,
396 Z.P.; Hou, E.C., *et al.* Long-term survival analysis in combined transarterial embolization and
397 stereotactic body radiation therapy versus stereotactic body radiation monotherapy for
398 unresectable hepatocellular carcinoma >5 cm. *BMC Cancer* **2016**, *16*, 834.
- 399 19. Su, T.S.; Luo, R.; Liang, P.; Cheng, T.; Zhou, Y.; Huang, Y. A prospective cohort study of
400 hepatic toxicity after stereotactic body radiation therapy for hepatocellular carcinoma.
401 *Radiother Oncol* **2018**, *129*, 136-142.
- 402 20. Scorsetti, M.; Comito, T.; Cozzi, L.; Clerici, E.; Tozzi, A.; Franzese, C.; Navarria, P.; Fogliata,
403 A.; Tomatis, S.; D'Agostino, G., *et al.* The challenge of inoperable hepatocellular carcinoma
404 (hcc): Results of a single-institutional experience on stereotactic body radiation therapy (sbrt).
405 *J. Cancer Res. Clin. Oncol.* **2015**, *141*, 1301-1309.
- 406 21. Rajyaguru, D.J.; Borgert, A.J.; Smith, A.L.; Thomes, R.M.; Conway, P.D.; Halfdanarson, T.R.;
407 Truty, M.J.; Kurup, A.N.; Go, R.S. Radiofrequency ablation versus stereotactic body
408 radiotherapy for localized hepatocellular carcinoma in nonsurgically managed patients:
409 Analysis of the national cancer database. *J Clin Oncol* **2018**, *36*, 600-608.
- 410 22. Shinde, A.; Jones, B.L.; Chen, Y.J.; Amini, A. Radiofrequency ablation versus stereotactic body
411 radiotherapy for localized hepatocellular carcinoma: Does radiation dose make a difference? *J*
412 *Clin Oncol* **2018**, *36*, 2566-2567.
- 413 23. Jang, W.; Kim, M.; Bae, S.; Cho, C.; Yoo, H.; Seo, Y.; Kang, J.; Kim, S.; Lee, D.; Han, C., *et*
414 *al.* High-dose stereotactic body radiotherapy correlates increased local control and overall
415 survival in patients with inoperable hepatocellular carcinoma. *Radiat Oncol* **2013**, *8*, 250.
- 416 24. Liu, X.; Song, Y.; Liang, P.; Su, T.; Zhang, H.; Zhao, X.; Yuan, Z.; Wang, P. Analysis of the
417 factors affecting the safety of robotic stereotactic body radiation therapy for hepatocellular
418 carcinoma patients. *Onco Targets Ther* **2017**, *10*, 5289-5295.
- 419 25. Liang, S.X.; Zhu, X.D.; Lu, H.J.; Pan, C.Y.; Li, F.X.; Huang, Q.F.; Wang, A.Y.; Chen, L.; Fu,
420 X.L.; Jiang, G.L. Hypofractionated three-dimensional conformal radiation therapy for primary
421 liver carcinoma. *Cancer* **2005**, *103*, 2181-2188.
- 422
423